AOM trends were plotted starting in April 2023 to allow time for medications to become available after FDA approval, people to initiate, and discontinue
That made up nearly two-thirds of Novo Nordisks entire revenue that year
doi: 10.2337/dc14-1984 157 NauckMAKemmeriesGHolstJJMeierJJ
The findings, which were presented over the weekend at ENDO 2026, the Endocrine Society's annual meeting, were based on an analysis of health records from more than 42,000 adults who were already taking at least two types of blood pressure medications when they began treatment with GLP-1 drugs such as semaglutide, tirzepatide or liraglutide
GLP-1 Side Effects Statistics 2026 | Nausea, Muscle Loss & Discontinuation Data GLP-1 Side Effects Statistics 2026: What the Clinical Trial Data Actually Shows An evidence-based look at how common GLP-1 side effects really are
Familiarizing yourself with common terms and identifying specific medications you're interested in can make the discussion more productive
)
